Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00517829 · ClinicalTrials.gov registry record · Phase 2

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

A Phase 2 study, sponsored by US Oncology Research.

Completed
Registry status
Phase 2
Development phase
150
Enrollment target

NCT00517829 is a Phase 2 study that has completed, run by US Oncology Research. The registered enrollment target is 150 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00517829, a Phase 2 study, has completed, sponsored by US Oncology Research.

COMPLETED
Registry status
Phase 2
Development phase
150 participants
Enrollment target

Study Summary

The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.

Interventions

  • DRUG Docetaxel
  • DRUG cetuximab
  • DRUG oxaliplatin

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2007-07
Est. Completion 2012-04
Phase Phase 2

Sponsor

US Oncology Research

27 total trials

What the Registry Record Tells You About NCT00517829

The ClinicalTrials.gov registry entry for NCT00517829 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.

NCT00517829 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00517829 about?

NCT00517829 is a clinical study titled "Docetaxel+Oxali+/-Cetux Met Gastric/GEJ". The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.

What is the current status of trial NCT00517829?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2007-07. Estimated completion is 2012-04.

What interventions are being tested in trial NCT00517829?

The interventions under investigation include: Docetaxel (DRUG), cetuximab (DRUG), oxaliplatin (DRUG).

Who is sponsoring clinical trial NCT00517829?

This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.